Literature DB >> 1329492

Ten-year follow-up after admission to methadone maintenance.

J F Maddux1, D P Desmond.   

Abstract

To assess the long-term effects of methadone maintenance, we compared the 10-year outcomes of 95 chronic opioid users who spent at least one cumulative year on methadone with those of 77 chronic opioid users who spent less than one cumulative year on methadone. All subjects were men and 90% were Mexican-American. The two groups were similar on 12 of 15 background variables. During the 10-year period, the methadone group had a cumulative mean of 54 months on methadone, while the comparison group had a cumulative mean of only 2 months on methadone. On social performance, as measured by months employed and months institutionalized, the methadone group did significantly better than did the comparison group. On months of voluntary abstinence, however, the comparison group did significantly better than did the methadone group. The mean of the comparison group, 36 months, was three times greater than that, 12 months, of the methadone group. At the end of the 10-year period, 26% of the comparison group but only 7% of the methadone group had been in continuous voluntary abstinence for 3 years or longer. Methadone maintenance for 1 year or longer was inversely related to abstinence during and at the end of the 10 years. This finding seems consistent with the hypothesis that methadone maintenance for 1 year or longer impedes eventual recovery from opioid dependence. For many patients, however, the benefits of prolonged maintenance could outweigh the possible cost of diminished likelihood of eventual recovery.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1329492     DOI: 10.3109/00952999209026068

Source DB:  PubMed          Journal:  Am J Drug Alcohol Abuse        ISSN: 0095-2990            Impact factor:   3.829


  7 in total

Review 1.  A risk-benefit analysis of methadone maintenance treatment.

Authors:  J Bell; D Zador
Journal:  Drug Saf       Date:  2000-03       Impact factor: 5.606

2.  30-year trajectories of heroin and other drug use among men and women sampled from methadone treatment in California.

Authors:  Christine E Grella; Katherine Lovinger
Journal:  Drug Alcohol Depend       Date:  2011-05-06       Impact factor: 4.492

3.  In Their Own Voices: Breaking the Vicious Cycle of Addiction, Treatment and Criminal Justice Among People who Inject Drugs in Ukraine.

Authors:  Alyona Mazhnaya; Martha J Bojko; Ruthanne Marcus; Sergii Filippovych; Zahedsul Islam; Sergey Dvoriak; Frederick L Altice
Journal:  Drugs (Abingdon Engl)       Date:  2016-02-16

4.  Leaving buprenorphine treatment: patients' reasons for cessation of care.

Authors:  Jan Gryczynski; Shannon Gwin Mitchell; Jerome H Jaffe; Kevin E O'Grady; Yngvild K Olsen; Robert P Schwartz
Journal:  J Subst Abuse Treat       Date:  2013-10-14

5.  Buprenorphine substitution treatment in France: drug users' views of the doctor-user relationship.

Authors:  Anne Guichard; France Lert; Jean-Marc Brodeur; Lucie Richard
Journal:  Soc Sci Med       Date:  2007-04-17       Impact factor: 4.634

Review 6.  Methadone maintenance treatment: an update.

Authors:  G Bertschy
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1995       Impact factor: 5.270

7.  Rationale, design and methods of VA-BRAVE: a randomized comparative effectiveness trial of two formulations of buprenorphine for treatment of opioid use disorder in veterans.

Authors:  Ismene Petrakis; Sandra A Springer; Cynthia Davis; Elizabeth Ralevski; Lucy Gu; Robert Lew; John Hermos; Melynn Nuite; Adam J Gordon; Thomas R Kosten; Edward V Nunes; Robert Rosenheck; Andrew J Saxon; Robert Swift; Alexa Goldberg; Robert Ringer; Ryan Ferguson
Journal:  Addict Sci Clin Pract       Date:  2022-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.